Trial Profile
New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jun 2023
Price :
$35
*
At a glance
- Drugs Ertapenem (Primary) ; Fosfomycin (Primary) ; Gentamicin (Primary) ; Ceftriaxone
- Indications Gonorrhoea
- Focus Therapeutic Use
- Acronyms NABOGO
- 01 Jun 2023 Results of secondary analysis (n=221) assessing the spontaneous clearance among patients with asymptomatic anal, pharyngeal, vaginal and urethral NG infections and the determinants associated with spontaneous clearance, participants from NABOGO trial, published in the Sexually Transmitted Infections.
- 01 May 2022 Primary endpoint (Proportion of participants with treatment success in each study arm for the included anatomic infection for fosfomycin arm/group) has not been met as per results published in The Lancet Infectious Diseases
- 01 May 2022 Primary endpoint (Proportion of participants with treatment success in each study arm for the included anatomic infection for Gentamicin arm/group) has not been met as per results published in The Lancet Infectious Diseases